Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

ABSTRACT:

Background

Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. Here, we used [¹⁸F]JNJ42259152 PET to measure changes in PDE10A availability, secondary to pharmacological alterations in DA release and to investigate whether these are D₁- or D₂-receptor driven.

Results

Acute treatment of rats using D-amphetamine (5 mg, s.c. and 1 mg/kg i.v.) did not result in a significant change in PDE10A BP_ND compared to baseline conditions. 5-day D-amphetamine treatment (5 mg/kg, s.c.) increased striatal PDE10A BP_ND compared to the baseline (+24 %, p = 0.03). Treatment with t

SUBMITTER: Ooms M 

PROVIDER: S-EPMC5843803 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature